The relationship of arterial hypertension, elevated low-density lipoprotein cholesterol and their combination with the occurrence of new cases of cardiovascular diseases in men and women of working age

Aim. To evaluate the contribution of arterial hypertension (AH), high lowdensity lipoprotein cholesterol (LDL-C) level and their combination to the development of (myocardial infarction) MI and stroke.

Material and methods. The analysis is based on data from 1 and 2 observations of ESSE-RF study (Epidemiology of cardiovascular diseases in various regions of the Russian Federation)". A multi-s tage cluster random sample was used, formed according to the territorial principle on the basis of medical and preventive institutions (health facilities). Socio-demographic data (gender, age, education, wealth), smoking status and medical history were determined. Blood pressure (BP) was measured twice, on the right arm, in a sitting position with an automatic blood pressure monitor. Blood samples and its derivatives (serum and plasma) were stored at a temperature of -70ºC. LDL-C value was also included into analysis (LDl- C ≥3 mmol/l). Prospective monitoring of new cases was carried out in the initial sample without patients with coronary artery disease, MI, and stroke. The median follow-up time is 7.5 years. The sample size was 19 794. 356 non-fatal cases were identified, including 222 cases of MI and 174 cases of stroke.

Results. The average age was 44.7 years, in men — 43.2, and in women — 45.3. The prevalence of isolated forms of hypertension, high LDL-C level and its combination were 12.7%, 30.3% and 32%, respectively. It was revealed that the age was the lowest in healthy and those with an increased LDL-C, whereas those with hypertension and combined conditions were older. The risk of nonfatal cases of MI and stroke in the Cox models, was adjusted for gender, age and region. There was a significantly higher risk of new cases of nonfatal CVD in individuals with isolated hypertension compared with those with isolated LDL-C.

Conclusion. The frequency of isolated AH and isolated LDL-C were 13% and 30%, respectively. The combined condition was detected in 30%. The presence of AH, isolated LDL-C and their combinations in the sample doubled the risk of new CVD events.

1. Liu T, Zhao D, Qi Y. Global Trends in the Epidemiology and Management of Dyslipidemia. J Clin Med. 2022;11(21):6377. DOI:10.3390/jcm11216377.

2. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-r epresentative studies with 104 million participants. Lancet. 2021;398(10304):957-80. DOI:10.1016/S01406736(21)01330-1.

3. Chow CK, Teo KK, Rangarajan S, et al; PURE (Prospective Urban Rural Epidemiology) Study investigators. Prevalence, Awareness, Treatment, and Control of Hypertension in Rural and Urban Communities in High-, Middle-, and Low-I ncome Countries. JAMA. 2013;310(9):959-68. DOI:10.1001/jama.2013.1841.

4. Prospective Studies Collaboration; Lewington S, Whitlock G, Clarke R, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370(9602):1829-39. DOI:10.1016/S01406736(07)61778-4.

5. Boytsov SA, Balanova YuA, Shalnova SA, et al. Arterial hypertension among individuals of 25–64 years old: prevalence, awareness, treatment and control. Cardiovascular Therapy and Prevention. 2014;13(4):4-14 (In Russ.) DOI:10.15829/1728-8800-20144-4-14.

6. Balanova YuA, Shalnova SA, Kutsenko VA, et al on behalf of the participants in the ESSAY-RF study. Contribution of arterial hypertension and other risk factors to survival and mortality in the Russian population. Cardiovascular Therapy and Prevention. 2021;20(5):3003 (In Russ.) DOI:10.15829/1728-8800-20213003.

7. Metelskaya VA, Shalnova SA, Deev AD, et al Analysis of atherogenic dyslipidemias prevalence among population of Russian Federation (results of the ESSE-RF Study). Profilakticheskaya Meditsina. 2016;19(1):15-23 (In Russ.) DOI:10.17116/profmed201619115-23.

8. Metelskaya VA, Shalnova SA, Yarovaya EB, et al. Lipoprotein Profile in Populations from Regions of the Russian Federation: ESSE-RF Study. Int J Environ Res Public Health. 2022;19(2):931. DOI:10.3390/ijerph19020931.

9. Tsao CW, Aday AW, Almarzooq ZI, et al; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association. Circulation. 2023;147(8):e93-e621. DOI:10.1161/CIR.0000000000001123.

10. Johnson ML, Pietz K, Battleman DS, Beyth RJ. Prevalence of comorbid hypertension and dyslipidemia and associated cardiovascular disease. Am J Manag Care. 2004;10(12):926-32.

11. Kobalava ZD, Kokhan EV. Hypertension and Hypercholesterolemia: is it Time for Anti-"Lipitensive" Therapy? Rational Pharmacotherapy in Cardiology. 2020;16(5):842-851 (In Russ.) DOI:10.20996/1819-6446-2020-09-01.

12. Grinshtein YuI, Shabalin VV, Ruf RR, et al. Prevalence of a combination of hypertension and dyslipidemia among the adult population of a large East Siberian region. Cardiovascular Therapy and Prevention. 2021;20(4):2865 (In Russ.) DOI:10.15829/1728-8800-2021-2865.

13. Boitsov SA, Chazov EI, Shlyakhto EV, et al. Scientific and Organizing Committee of the Russian Federation essay. Epidemiology of cardiovascular diseases in different regions of Russia (ESSE-RF). The rationale for and design of the study. The Russian Journal of Preventive Medicine. 013;16(6):25-34 (In Russ.)

14. Wong ND, Lopeza V, Tang S, Williams GR. Prevalence, Treatment, and Control of Combined Hypertension and Hypercholesterolemia in the United States. Am J Cardiol. 2006;98(2):204-8. DOI:10.1016/j.amjcard.2006.01.079.

15. Kutkiene S, Petrulioniene Z, Laucevicius A, et al. Cardiovascular risk assessment of dyslipidemic middle-aged adults without overt cardiovascular disease over the period of 2009-2016 in Lithuania. Lipids Health Dis. 2018;17(1):233. DOI:10.1186/s12944-018-0883-5.

16. Dzizinsky AA. Etiological and clinical pathogenetic interrelations of atherosclerosis and arterial hypertension. Siberian Medical Journal (Irkutsk). (In Russ.)

17. Dalal JJ, Padmanabhan TN, Jain P, et al. LIPITENSION: Interplay between dyslipidemia and hypertension. Indian J Endocrinol Metab. 2012;16(2): 240-5. DOI:10.4103/2230-8210.93742.

18. Yusuf S, Hawken S, Ounpuu S, et al; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004; 364(9438):937-52. DOI:10.1016/S0140-6736(04)17018-9.2.

19. O’Donnell MJ, Chin SL, Rangarajan S, et al; INTERSTROKE investigators. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet. 2016;388(10046):761-75. DOI:10.1016/S0140-6736(16)30506-2.

20. Xie H, Zhuang Q, Mu J, et al The relationship between lipid risk score and new-onset hypertension in a prospective cohort study. Front Endocrinol (Lausanne). 2022;13:916951. DOI:10.3389/fendo.2022.916951.